Results 61 to 70 of about 119,936 (354)

Risk factors of osimertinib-related cardiotoxicity in non-small cell lung cancer

Frontiers in Oncology
ObjectiveTo investigate the risk factors associated with cardiotoxicity in patients with non-small cell lung cancer (NSCLC) treated with osimertinib.MethodsA total of 268 patients with NSCLC treated with osimertinib in our hospital from June 2019 to ...
Yunlong Wang, Xuan Deng, Qinggui Qiu, Mengchao Wan   +3 more
doaj   +1 more source

Risk Compounds, Preclinical Toxicity Evaluation, and Potential Mechanisms of Chinese Materia Medica–Induced Cardiotoxicity

Frontiers in Pharmacology, 2021
Chinese materia medica (CMM) has been applied for the prevention and treatment of diseases for thousands of years. However, arrhythmia, myocardial ischemia, heart failure, and other cardiac adverse reactions during CMM application were gradually reported.
Jie Zhou, Jie Zhou, Jie Zhou, Fu Peng, Xiaoyu Cao, Xiaoyu Cao, Xiaofang Xie, Xiaofang Xie, Dayi Chen, Lian Yang, Chaolong Rao, Cheng Peng, Cheng Peng, Xiaoqi Pan, Xiaoqi Pan   +14 more
doaj   +1 more source

Functional impairment of human resident cardiac stem cells by the cardiotoxic antineoplastic agent trastuzumab [PDF]

, 2012
Trastuzumab (TZM), a monoclonal antibody against the ERBB2 protein, increases survival in ERBB2-positive breast cancer patients. Its clinical use, however, is limited by cardiotoxicity. We sought to evaluate whether TZM cardiotoxicity involves inhibition
A. c. Wolff, A. s. Barth, A. s. Ho, B. O'Rourke, CHIMENTI, ISOTTA, D. r. Davis, E. Kizana, E. Marban, G. Gerstenblith, I. Terrovitis, R. r. Smith, T. s. Li, Y. Zhang   +12 more
core   +1 more source

Doxorubicin causes ferroptosis and cardiotoxicity by intercalating into mitochondrial DNA and disrupting Alas1-dependent heme synthesis

Science Signaling, 2022
Clinical use of doxorubicin (DOX) is limited because of its cardiotoxicity, referred to as DOX-induced cardiomyopathy (DIC). Mitochondria-dependent ferroptosis, which is triggered by iron overload and excessive lipid peroxidation, plays a pivotal role in
K. Abe, Masataka Ikeda, T. Ide, T. Tadokoro, H. Miyamoto, Shun Furusawa, Yoshitomo Tsutsui, Ryo Miyake, Kosei Ishimaru, Masatsugu Watanabe, Shouji Matsushima, T. Koumura, Ken‐ichi Yamada, H. Imai, H. Tsutsui   +14 more
semanticscholar   +1 more source

Dibucaine in Ionic-Gradient Liposomes: Biophysical, Toxicological, and Activity Characterization [PDF]

, 2018
Administration of local anesthetics is one of the most effective pain control techniques for postoperative analgesia. However, anesthetic agents easily diffuse into the injection site, limiting the time of anesthesia. One approach to prolong analgesia is
Alonso, Silvia del Valle, Castro, Simone R., Couto, Verônica M., Dantzger, Darlene D., de Paula, Eneida, Feas, Daniela Agustina, Guilherme, Viviane A., Igartúa, Daniela, Machado, Daisy, Prieto, Maria Jimena, Ribeiro, Lígia N.M., Silva, Camila M.G.   +11 more
core   +1 more source

Role of Oxidative Stress and Inflammation in Doxorubicin-Induced Cardiotoxicity: A Brief Account

International Journal of Molecular Sciences
Cardiotoxicity is the main side effect of several chemotherapeutic drugs. Doxorubicin (Doxo) is one of the most used anthracyclines in the treatment of many tumors, but the development of acute and chronic cardiotoxicity limits its clinical usefulness ...
Roberta Vitale, S. Marzocco, A. Popolo
semanticscholar   +1 more source

Cardiotoxicity in patients with metastatic melanoma treated with BRAF/MEK inhibitors: a real-world analysis of incidence, risk factors, and reversibility

Acta Oncologica
Background: BRAF/MEK inhibitors (BRAFi/MEKi) improve outcome in patients with BRAF-mutated metastatic melanoma but are associated with cardiotoxicity, leading to a decline in left ventricular ejection fraction (LVEF).
Jonas K. Oddershede, Ida K. Meklenborg, Lars Bastholt, Louise M. Guldbrandt, Henrik Schmidt, Rasmus B. Friis   +5 more
doaj   +1 more source

A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors

Frontiers in Pharmacology, 2020
Numerous protein kinases encoded in the genome have become attractive targets for the treatment of different types of cancer. As of January 2020, a total of 52 small-molecule kinase inhibitors (SMKIs) have been approved by the FDA.
Ying Jin, Zhifei Xu, Hao Yan, Qiaojun He, Xiaochun Yang, Peihua Luo   +5 more
doaj   +1 more source

Clinical Manifestations, Monitoring, and Prognosis: A Review of Cardiotoxicity After Antitumor Strategy

Frontiers in Cardiovascular Medicine, 2022
The development of various antitumor drugs has significantly improved the survival of patients with cancer. Many first-line chemotherapy drugs are cytotoxic and the cardiotoxicity is one of the most significant effects that could leads to poor prognosis ...
Wei Huang, Rong Xu, Bin Zhou, Chao Lin, Yingkun Guo, Huayan Xu, Xia Guo   +6 more
doaj   +1 more source

Current perspective - Trastuzumab [PDF]

, 2009
This article will review the available clinical data on the efficacy of trastuzumab in the treatment of both early advanced breast ...
Cameron, D.A., Hall, P.S.
core   +1 more source